Literature DB >> 9474220

Comparison of percutaneous endopyelotomy with open pyeloplasty for pediatric ureteropelvic junction obstruction.

E M Schenkman1, W F Tarry.   

Abstract

PURPOSE: Percutaneous endopyelotomy has been shown to be effective in the management of ureteropelvic junction obstruction in adults and secondary ureteropelvic junction obstruction in children. There are little published data regarding endopyelotomy as a primary treatment in children.
MATERIALS AND METHODS: During 3 years we performed 8 endopyelotomies and 20 open pyeloplasties for primary ureteropelvic junction obstruction and compared the results. Preoperative ureteropelvic junction obstruction was detected by renal ultrasound, excretory urogram (IVP) or renal scan. All patients were followed 1.5 to 3 years postoperatively. The success of the procedure was determined by excretory urogram, renal scan or the absence of clinical findings, with 1 failure in each group.
RESULTS: The overall success rates for endopyelotomy and open pyeloplasty were 88% and 93%, respectively. Hospital stays were essentially equal between the groups but operative time and hospital costs were higher for endopyelotomy.
CONCLUSIONS: Endopyelotomy may be performed effectively for primary ureteropelvic junction obstruction in children but with increased costs.

Entities:  

Mesh:

Year:  1998        PMID: 9474220

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Percutaneous endopyelotomy for ureteropelvic junction obstruction.

Authors:  Akiou Okumura; Hideki Fuse; Shinji Tsuritani; Tetsuo Nozaki
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  The role of endourology in ureteropelvic junction obstruction.

Authors:  P J Van Cangh; S Nesa; B Tombal
Journal:  Curr Urol Rep       Date:  2001-04       Impact factor: 2.862

3.  Single session endoscopic management of intrinsic ureteropelvic junction obstruction and concomitant renal stone disease in a child: a case report.

Authors:  Murat Ugras; Ali Gunes; Ugur Yilmaz; Can Baydinc
Journal:  BMC Urol       Date:  2002-09-24       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.